## Patient agreement to systemic anti-cancer

the reserve (CACT).	
therapy (SACT):	Patient's first name(s):
Chlorambucil	
Cittorarribacit	Date of birth:
	NHS number:
	(or other identifier)
Hospital/NHS Trust/NHS Board:	Special requirements:  (e.g. other language/other communication method)
Responsible consultant:	
Name:	
Job title:	
Name of proposed course of treatment (include	e brief explanation if medical term not clear)
☐ Chlorambucil for the treatment of chronic lympho	ocytic leukaemia (CLL).
Chlorambucil is taken orally each day (in divided deperiod).	oses) on days 1 to 7 (followed by a 21 day rest
Each treatment cycle lasts for 28 days (one cycle).	
☐ Treatment is continued for up to 12 cycles.	
Where the treatment will be given	
☐ Outpatient ☐ Day unit/case ☐ Inpatient ☐	Other:
Statement of health professiona	
(to be filled in by health professional with appropriate knowledge board's consent policy)	e of proposed procedure, as specified in the hospital/Trust/NH
☑ Tick all relevant boxes	
☐ I confirm the patient has capacity to give consent.	
☐ I have explained the course of treatment and intend	ded benefit to the patient.
The intended benefits (there are no guarantees abou	ut outcome)
Disease control— the aim is not to cure but to control	
$\square$ To obtain or maintain remission of your leukaemia, i	in order to improve both quality and quantity of life.

Patient details

Patient's surname/family name:

### Statement of health professional

More than 10 in every 100 (>10%) people have one or more

An increased risk of getting an infection from a drop in white blood cells - it is harder to fight infections and you can become very ill.
 If you have a severe infection this can be life threatening. Contact your doctor or hospital

your chemotherapy team

normal temperature)

Anaemia (low red blood cells).

mouth and ulcers, diarrhoea.

later), particularly of the blood.

your temperature goes over 37.5°C or over 38°C, depending on the advice given by

you suddenly feel unwell (even with a

Between 1 and 10 in every 100 (1-10%) people have one or

Feeling sick (nausea), being sick (vomiting), sore

Increased risk of tumour lysis syndrome (when treatment destroys cancer cells too quickly for the kidneys to cope). Rarely, dialysis is needed.

Effects on the nervous system are rare, causing

monitored), causing yellowing of the skin and

You will be prescribed medicines for

Changes in how the liver works (which is

Allergic reactions to Chlorambucil are rare.
 Changes in the lungs (inflammation or scarring) causing cough or breathlessness. Let your doctor know if you have difficulty breathing or shortness of breath while at rest or gentle

seizures, fits and tremors.

An increased risk of a second cancer (years

(continued)

Common side effects:

of the side effects listed:

straight away if:

Bruising and bleeding.

Occasional side effects:

more of these effects:

Other risks:

prevention.

activity.

Significant, unavoidable or frequently occurring risks

Ot	her risks continued:
	Skin changes (rashes, peeling) are uncommon. Severe skin reactions (Steven Johnson Syndrome or Toxic Epidermal Necrolysis) are rare.
	Changes in your memory, concentration or ability to think clearly. There can be many causes including your treatment, diagnosis, or both.
	Before treatment, you might have blood tests to check for viruses (Hepatitis B, Hepatitis C, HIV or more unusual infections). This treatment may weaken your natural defence (immune) system, so infections like this could worsen or become active again if you've had them in the past. You may have medicines to prevent or treat infection.
	Some anti-cancer medicines can damage ovaries and sperm. This may lead to infertility and/or early menopause.
	Some anti-cancer medicines may damage the development of a baby in the womb. It is important not to become pregnant or make someone else pregnant during treatment and for several months afterwards. Use effective contraception during this time. You can talk to your doctor or nurse.
	Complications of treatment can very occasionally be life threatening and may result in death. The risks are different for every individual. Potentially life threatening complications include those listed on this form, but, other, exceedingly rare side-effects may also be life threatening.

Patient identifier/label

To be retained in patient notes
Prepared by Pharmacist: Lucy Cox
Checked by Pharmacist: Llywelyn Cadman-Davies
Checked by Consultant: Piers Patten

## Statement of health professional

(continued)

D 1: 1		/1 1 1
Dationt	identifier	/Ianai
rauciii	idel idilet	/ label

Any other risks and information		
I have discussed the intended benefit and risks of the alternative treatments (including no treatment).	ne recommended treatment, and of any available	
I have discussed the side effects of the recommend away or in the future, and that there may be some side been reported. Each patient may experience side effects	effects not listed because they are rare or have not yet	
I have discussed what the treatment is likely to invo of the treatment, blood and any additional tests, follow	lve (including inpatient / outpatient treatment, timing	
☐ I have explained to the patient, that they have the riccontact the responsible consultant or team if they wish		
I have discussed concerns of particular importance (please write details here):		
Clinical management guideline/Protocol comp    Yes	lliant (please tick):	
If No please document reason here:		
' 		
The following written information has	Health professional details:	
been provided:	Signed:	
☐ Information leaflet for Chlorambucil	Date:	
☐ 24 hour alert card or SACT advice service contact details	Name (PRINT):	
SACT treatment record (cruk.org/treatment-record)	Job title:	
☐ Other, please state:		
Statement of interpreter (where appro		
Interpreter booking reference (if applicable):		
I have interpreted the information above to the patient they can understand.	to the best of my ability and in a way in which I believe	
Signed:Date:		
Name (PRINT):		
Job title:		

### Statement of patient

Patient identifier/label

own copy of the form which describes the benefits and risks of the proposed treatment. If not, you will be offered a copy now. If you have any further questions, do ask – we are here to help you. You have the right to change your mind at any time, including after you have signed this form.

I have had enough time to consider my options and make a decision about treatment.

I agree to the course of treatment described on this form.

A witness should sign below if the patient is unable to sign but has indicated their consent. A person with parental responsibility will be asked to sign for young people under the age of 16 years.

Patient's signature:

Name (PRINT):

Date:

Date:

Date:

Date:

Please read this form carefully. If your treatment has been planned in advance, you should already have your

## Copy accepted by patient: yes / no (please circle)

Confirmation of consent (health professional to complete when the patient attends for treatment, if the patient has signed the form in advance)
On behalf of the team treating the patient, I have confirmed that the patient has no further questions and wishes the course of treatment/procedures to go ahead.  Signed:
Date:
Name (PRINT):
Job title:
Important notes: (tick if applicable)  See also advance decision to refuse treatment  Patient has withdrawn consent
(ask patient to sign /date here)
Signed:
Date:

## Further information for patients

Contact details (if patient wishes to discuss options later):

Contact your hospital team if you have any questions about cancer and its treatment.

Cancer Research UK can also help answer your questions about cancer and treatment. If you want to talk in confidence, call our information nurses on freephone **0808 800 4040**, Monday to Friday, 9am to 5pm. Alternatively visit **www.cruk.org** for more information.

These forms have been produced by Guy's and St. Thomas' NHS Foundation Trust as part of a national project to support clinicians in ensuring all patients are fully informed when consenting to SACT.

The project is supported by Cancer Research UK. This does not mean you are taking part in a clinical trial.



# Guidance for health professionals (to be read in conjunction with

the hospital's consent policy)

#### What a consent form is for

This form documents the patient's agreement to go ahead with the treatment you have proposed. It is not a legal waiver – if patients, for example, do not receive enough information on which to base their decision, then the consent may not be valid, even though the form has been signed. Patients are also entitled to change their mind after signing the form, if they retain capacity to do so. The form should act as an aidememoir to health professionals and patients, by providing a checklist of the kind of information patients should be offered, and by enabling the patient to have a written record of the main points discussed. In no way should the written information provided for the patient be regarded as a substitute for face-to-face discussions with the patient.

#### The law on consent

See the following publications for a comprehensive summary of the law on consent. Consent: Patients and doctors making decisions together, GMC 2020 (www.gmc-uk.org/guidance). Reference guide to consent for examination or treatment, Department of Health, 2nd edition 2009 (www.doh.gov.uk).

#### Who can give consent

Everyone aged 16 or over is presumed to have the capacity to give consent for themselves, unless the opposite is demonstrated. For young people, it is good practice to involve those with parental responsibility in the consent discussions, unless specifically asked not to. A person with parental responsibility must sign this form for a child or young person under the age of 16. Such patients should be given the opportunity to 'assent' to treatment if they wish. If a patient has the capacity to give consent but is physically unable to sign a form, you should complete this form as usual and ask an independent witness to confirm that the patient has given consent orally or non-verbally.

#### When NOT to use this form

If the patient lacks the capacity to give consent, you should use an alternative form available for this purpose (dependent on patient age). A patient lacks capacity if they have an impairment or disturbance of the brain, affecting the way their mind works. For example, if they cannot do one of the following:

- understand information about the decision to be made
- retain that information in their mind
- use or weigh this information as a part of their decision making process, or

Patient identifier/label

communicate their decision (by talking, using sign language or any other means)

You should always take all reasonable steps (for example involving more specialist colleagues) to support a patient in making their own decision, before concluding that they are unable to do so.

Relatives cannot be asked to sign a form on behalf of an adult who lacks capacity to consent for themselves, unless they have been given the authority to do so under a Lasting Power of Attorney or as a court deputy.

#### Information

Information about what the treatment will involve, its benefits and risks (including side-effects and complications) and the alternatives to the particular procedure proposed, is crucial for patients when making up their minds. The courts have stated that patients should be told about 'significant risks which would affect the judgement of a reasonable patient'. 'Significant' has not been legally defined, but the GMC requires doctors to tell patients about 'significant, unavoidable or frequently occurring' risks. In addition if patients make clear they have particular concerns about certain kinds of risk, you should make sure they are informed about these risks, even if they are very small or rare. You should always answer questions honestly. Sometimes, patients may make it clear that they do not want to have any information about the options, but want you to decide on their behalf. In such circumstances, you should do your best to ensure that the patient receives at least very basic information about what is proposed. Where information is refused, you should document this on the consent form or in the patient's notes.

### **NHS Scotland**

NHS Scotland staff should refer to Healthcare Improvement Scotland. Guidance on consent for SACT and local NHS Board guidance on consent aligned to the Scotlish legal framework.

#### References

- Summary of Product Characteristics (SmPCs) for individual drugs: https://www.medicines.org.uk/emc
- 2. Cancer Research UK: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs
- Macmillan Cancer Support: https://www.macmillan.org.uk/ information-and-support/treating/chemotherapy/drugs-andcombination-regimens
- 4. Guy's and St. Thomas' NHS Foundation Trust, Chemotherapy consent